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Abstract
Purpose
Rectal cancer patients achieving pCR are known to have an excellent prognosis, yet no
widely accepted consensus on risk stratification and post-operative management (e.g.,
adjuvant therapy) has been established. This study aimed to identify magnetic resonance
imaging (MRI) high-risk factors for tumor relapse in pathological complete remission (pCR)
achieved by rectal cancer patients who have undergone neoadjuvant concurrent chemora-
diation therapy (CRT) and curative resection.
Materials and Methods
We analyzed 88 (male/female = 55/33, median age, 59.5 years [range 34–78]) pCR-proven
rectal cancer patients who had undergone pre-CRT MRI, CRT, post-CRT MRI and curative
surgery between July 2005 and December 2012. Patients were observed for post-operative
tumor relapse. We analyzed the pre/post-CRT MRIs for parameters including mrT stage,
mesorectal fascia (mrMRF) status, tumor volume, tumor regression grade (mrTRG), nodal
status (mrN), and extramural vessel invasion (mrEMVI). We performed univariate analysis
and Kaplan-Meier survival analysis.
Results
Post-operative tumor relapse occurred in seven patients (8.0%, n = 7/88) between 5.7 and
50.7 (median 16.8) months. No significant relevance was observed between tumor volume,
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volume reduction rate, mrTRG, mrT, or mrN status. Meanwhile, positive mrMRF (Ppre-CRT =
0.018, Ppre/post-CRT = 0.006) and mrEMVI (Ppre-CRT = 0.026, Ppre-/post-CRT = 0.008) were asso-
ciated with higher incidence of post-operative tumor relapse. Kaplan-Meier survival analysis
revealed a higher risk of tumor relapse in patients with positive mrMRF (Ppre-CRT = 0.029,
Ppre-/post-CRT = 0.009) or mrEMVI (Ppre-CRT = 0.024, Ppre-/post-CRT = 0.003).
Conclusion
Positive mrMRF and mrEMVI status was associated with a higher risk of post-operative
tumor relapse of pCR achieved by rectal cancer patients, and therefore, can be applied for
risk stratification and to individualize treatment plans.
Introduction
Neoadjuvant concurrent chemoradiation therapy (CRT) has been increasingly used to treat
locally advanced rectal cancer. It has been proven to reduce local tumor recurrence and toxicity
when compared with post-operative chemoradiation therapy [1]. Moreover, approximately
10–30% of rectal cancer patients achieve pathological complete remission (pCR) after CRT [2–
4]. These patients are known to carry a very low risk of lymph node (LN) metastasis and to
experience excellent overall and disease-free survival [5–7]. Therefore, if a rectal cancer patient
who has undergone CRT and subsequent surgery is documented as pCR, then a preferable
prognosis can be anticipated.
With the widespread use of CRT in rectal cancer, we now encounter increasing numbers of
patients who reach pCR. However, this encouraging condition of absent residual viable tumor
cells upon histopathological analysis has raised several issues.
One unsolved controversy is how to manage pCR achieved rectal cancer patients after stan-
dard treatment. Currently, CRT followed by radical surgery is the standard treatment of locally
advanced rectal cancer and ensures excellent local control of pCR patients. The prognosis of
pCR achieved patients are expected to be excellent, therefore it is not clear whether these
patients should be managed same as other patients who do not achieve pCR. Collectively, we
envision that risk stratification of pCR patients who already completed standard CRT and
curative surgery is necessary.
MRI is an established imaging tool, which is widely used for local staging of rectal cancer.
We hypothesized that certain MRI features may be associated with a higher risk of tumor
relapse in pCR rectal cancer patients after surgery, which could be applied for risk stratifica-
tion, useful towards individualizing treatment strategies, as well as predicting prognosis.
The purpose of this study was to identify high-risk MRI features associated with tumor
relapse in pCR-achieved rectal cancer patients who had undergone standard CRT and curative
surgery.
Material and Methods
Study population and identification of tumor-recurred patients
This retrospective study was approved by the institutional review board of Severance Hospital,
and a waiver for informed consent was obtained (Approval number: 4-2014-0177). All the data
were analyzed anonymously. We screened 93 consecutive pCR (Mandard grade 1) rectal cancer
patients who had undergone an elective resection after CRT between July 2005 and December
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2012. We defined the pCR state as having no residual viable tumor cells in the primary rectal
mass irrespective of lymph node involvement. Those patients lacking pre- and/or post-CRT
rectal MRIs (n = 5) were excluded. No patients had evidence of synchronous distant metastasis
at the pre-operative period. Ultimately, our final study population consisted of 88 pCR patients
(male/female = 55/33, and median age, 59.5 years [range 34–78]).
Patient and tumor characteristics, including the type of treatment, serum CEA, and patho-
logic results were noted. Medical records and reports of post-operative surveillance imaging
studies were reviewed until December 2014 to identify tumor relapse and/or mortality events.
The median follow-up period, calculated from the date of surgery, was 49.0 months (range,
17.7 to 106.7 months). The relapse-free period (RFP) was defined as the time period between
the date of the surgery and the date when tumor recurrence was first diagnosed.
Patient treatment
All patients received CRT. The principle of deciding to proceed with pre-CRT was based on 1)
a clinical MR stage of T3/T4 cancer irrespective of the N stage or any T with positive N status,
or 2) any lower rectal cancer located near the sphincter complex, and 3) no identifiable distant
metastasis detectable by other imaging modalities. CRT was performed as previously described
[8]. Radiation therapy was delivered at an energy level of 6 MV/10 MV. A total dose of 45 Gy
was irradiated in 25 fractions to the pelvis over the course of five weeks (1.8 Gy/day, five days/
week). A subsequent 5.4 Gy boost targeting the primary tumor was delivered. The regimen of
concurrent chemotherapy included 5-fluorouracil and leucovorin (n = 60), capecitabine
(n = 6), and S-1 plus irinotecan (n = 22). Patients underwent surgery between six and eight
weeks following the completion of CRT. The standard method of surgery was total mesorectal
excision, and curative resection was performed on all patients without residual cancer. Surgical
resection was classified as low anterior resection, ultra-low anterior resection, or abdominoper-
ineal resection. After surgery, 65 patients received adjuvant chemotherapy either with the FOL-
FOX protocol (n = 59), capecitabine (n = 5), or the FOLFIRI protocol with bevacizumab
(n = 1), while 23 patients did not receive adjuvant chemotherapy (Table 1).
Image acquisition and analysis
Post-CRT MRIs were obtained 3–5 weeks before surgery. MR imaging was performed as previ-
ously described [9, 10] with either a 1.5T scanner (Achieva; Philips Medical Systems, Best, The
Netherlands) or 3.0T scanner (Magnetom Tim Trio; Siemens Medical Solutions, Erlangen,
Germany). T2-weighted MR images were obtained in axial, sagittal, oblique axial, and coronal
orientations using a respiratory-triggered echo train spin echo sequence.
All MR images were analyzed on a picture-archiving and communicating system worksta-
tion (Centricity, GE Healthcare, Milwaukee, WI, USA). Two gastrointestinal radiologists (H.K.
and J.S.L., with four years and 12 years of experience in abdominal imaging, respectively) spe-
cializing in rectal cancer evaluation, retrospectively reviewed the MR images on consensus.
The reviewers were aware that the patients achieved a pCR state, but were blinded to all other
clinical information.
The pre-CRT MRI T2-weighted sagittal image was used to classify the tumor’s distal margin
level (upper rectum, n = 1; middle rectum, n = 26; lower rectum & anal canal, n = 61): Three
imaginary lines, each connecting the center of the symphysis pubis and 1) sacral promontory,
2) peritoneal reflection, and 3) intervertebral junction between the 5th sacral bone and the coc-
cyx were drawn to divide the rectum into three compartments (S1 Fig).
To measure the tumor volume, the T2-weighted oblique axial images were archived in Digi-
tal Imaging and Communications in Medicine (DICOM) format, and stored on a General
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Electric Advantage workstation version 4 (GE Healthcare, Waukesha, WI, USA). The region of
interest (ROI) was drawn along the margin of the rectal mass on each slice, and the area of the
ROI obtained from each image was added to calculate the total mass volume. The volume
reduction rate was calculated according to the following equation: volume reduction rate (%) =
(Volumepre-CRT−Volumepost-CRT)/Volumepre-CRT☓ 100.
The MRI tumor regression grade (mrTRG) was assigned into one of the two categories
(mrTRG1/2 vs. mrTRG3/4/5) to simplify statistical analysis based on the comparison of pre-/
post-CRTMRIs. For mrTRG1/2, the residual tumor is absent (mrTRG1) or only a small residual
tumor with a predominant fibrotic low-signal intensity remains (mrTRG2). For mrTRG3/4/5,
all other lesions are included that do not meet the criteria of mrTRG 1 or 2 (modified from
[11]).
The MRI T (mrT) stage was classified as a low mrT stage group (mrT1/2: tumor is confined
within rectal muscularis propria and mrT3<5mm: tumor extent is<5 mm beyond the muscu-
laris propria) or as a high mrT stage group (mrT35mm: tumor extent5 mm beyond
Table 1. Patient characteristics.
Variables No. Patients %
Age (years)
Range 34–78 (median 59.5)
Sex
Male 55 (63)
Female 33 (38)
Tumor level (MR classiﬁcation of the distal margin)
Upper 1 (1)
Middle 26 (30)
Lower (including anal canal) 61 (69)
Histologic grade (biopsy)
Well-differentiated 21 (24)
Moderately differentiated 61 (69)
Poorly differentiated 3 (3)
Mucinous 3 (3)
Pathologic LN metastasis 4 (5)
Pre-CRT protocol
5-ﬂuorouracil+leucovorin 60 (68)
Capecitabine 6 (7)
Irinotecan/TS-1 22 (25)
Adjuvant chemotherapy
None 23 (26)
FOLFOX protocol 59 (67)
Capecitabine 5 (6)
FOLFIRI protocol + Avastin 1 (1)
Type of resection
Low anterior resection 53 (60)
Ultra-low anterior resection with colo-anal anastomosis 31 (35)
Abdominoperineal resection 4 (5)
CEA, carcinoembryonic antigen; CRT, neoadjuvant concurrent chemoradiotherapy; LN, lymph node; MR,
magnetic resonance.
doi:10.1371/journal.pone.0146235.t001
MRRisk Stratification pCR Rectal Cancer Relapse
PLOS ONE | DOI:10.1371/journal.pone.0146235 January 5, 2016 4 / 13
muscularis propria and mrT4: invasion of other organs) [11]. A patient was considered to be
an mrT down-staged case if graded as mrT35mm on pre-CRT but mrT3<5mm on post-CRT
MRI.
The MRI mesorectal fascia (mrMRF) was defined as a T2 dark signal intensity linear struc-
ture encasing the rectum and perirectal fat. The mrMRF status was graded according to the
shortest distance from the tumor outermost margin to the adjacent MRF and labeled as nega-
tive (2 mm) or positive (<2 mm) [12–14]. If a patient’s MRF status was initially graded as
positive on pre-CRT MRI, but on the post-CRT MRI the mass decreased and a fat pad thicker
than 2mm appeared between the residual mass (with or without fine speculation) and the
MRF, then the post-CRT MRI MRF status was graded as negative [15].
The MRI extramural vessel invasion (mrEMVI) status was graded as negative or positive.
EMVI was considered positive when a gross vessel adjacent to the tumor presented with an
irregular contour showing either nodular expansion or contained intermediate signal intensity
[16].
The MRI regional LN (mrN) status was assigned into one of two groups (negative vs. posi-
tive for metastasis). The nodal status was considered negative if the largest LN short diameter
was< 6 mm and the LN had an irregular border or mixed signal intensity was absent. Positive
LNs were defined as LNs with a short diameter 6 mm and/or a LN presenting with an irregu-
lar border and/or mixed SI [17].
Statistical analysis
Statistical analysis was done using the SPSS version 20.0 (IBM Corp., Armonk, NY, USA) soft-
ware package. Fisher’s exact test was used to compare age (60,>60), sex, CRT protocol, adju-
vant chemotherapy protocol, tumor level, mrTRG, mrT stage, mrMRF status, mrEMVI status,
and mrN status. Independent t-test was conducted to compare CEA levels, tumor volume, and
volume reduction rate between the tumor-relapsed group and the non-relapsed group.
Survival analysis using the Kaplan-Meier method was performed to calculate the estimated
probability of the overall tumor relapse rate and overall survival rate. Time to tumor relapse
was calculated from the date of surgery to the date when the tumor relapse was first discovered.
Log-rank method was used to compare different data sets. Data were censored at the time of
the last follow-up. Because of the small number of tumor recurrences, we did not perform mul-
tivariate analysis. Statistical significance was accepted for differences with P values of less than
0.05.
Results
Among the 88 pCR patients, seven tumor relapses occurred (8.0%, n = 7/88) for which the RFP
ranged from 5.7 to 50.7 (median 16.8) months. Tumor recurrence occurred at the anastomosis
site (n = 1, RFP: 50.7 months), para-aortic space node (n = 1, RFP: 7.3 months), liver (n = 2,
RFP: 5.7, 42.2 months), and lung (n = 3, RFP: 10.8, 22.9, 37.4 months) (Fig 1). The level of rec-
tal cancer in these tumor-relapsed patients was as the middle rectum (n = 3) or lower rectum
(n = 4). The relapsed tumor lesion was confirmed either by biopsy or elective resection in all
seven cases. All seven relapsed patients had received adjuvant chemotherapy before tumor
relapse developed. Three deaths occurred among these seven patients due to progression of the
relapsed tumor (S1 Table). Meanwhile, the relapsed tumor lesions in the other four patients
were successfully controlled by additional surgical interventions and systemic chemotherapy.
No mortalities occurred in the non-relapsed group.
The level of the tumor distal margin did not show statistical significance with respect to
the tumor relapse (P = 0.468). The pre-CRT CEA level between tumor-relapsed patients
MRRisk Stratification pCR Rectal Cancer Relapse
PLOS ONE | DOI:10.1371/journal.pone.0146235 January 5, 2016 5 / 13
(16.0±6.1 ng/mL) and non-relapsed patients (4.0±6.0 ng/mL) did not show a statistically signif-
icant difference (P = 0.471). There were no significant clinical factors associated with tumor
relapse in pCR patients (S2 Table).
The tumor volume measured on both the pre- and post-CRTMRIs did not differ between the
non-relapse group (pre-CRT: 0.4–144.3, 23.9±24.4 cm3; post-CRT: 0–46.2, 7.4±8.9 cm3) and the
tumor relapse group (pre-CRT: 5.6–81.6: 30.1±24.9 cm3; post-CRT: 1.0–32.8: 10.3±11.1 cm3),
showing no statistically significant difference (Ppre-CRT = 0.516; Ppost-CRT = 0.421). No statistically
significant differences were seen in the volume reduction rate (P = 0.962) between the tumor non-
relapse group (13.3–100: 70.7±19.8%) and the tumor relapse group (50.8–87.2: 70.3±14.0%). The
mrTRG assessment did not show a difference in tumor relapse (P = 1.0) between mrTRG1/2
(n = 26; two tumor relapses) and mrTRG3/4/5 (n = 62; five tumor relapses), (S3 Table).
On pre-CRT MRI, the low mrT stage group (n = 46; three tumor recurrences) and the
high mrT stage group (n = 42; four tumor recurrences) did not show a significant difference
in tumor relapse (P = 0.705). Comparison of pre-/post-CRT MR revealed that down staging
of the T stage occurred in 14 patients; therefore, the low mrT stage was re-grouped to include
60 patients (46 persistently low mrT stage and 14 down-staged patients). However, no statis-
tically significant difference in terms of tumor recurrence was observed between these two
groups (tumor relapse/low mrT vs. persistently high mrT: n = 4/60 vs. 3/28; P = 0.675)
(S3 Table).
The mrMRF status on pre-CRTMRI showed a statistically significant relevance with respect
to tumor relapse, as all tumor relapses developed among positive mrMRF patients (tumor
relapse/negative vs. positive mrMRF: n = 0/37 vs. 7/51; P = 0.018). The comparison of pre-/
post-CRT MRIs identified seven cases of negative mrMRF conversions; therefore, the negative
group was re-grouped to consist of 44 patients (no tumor relapses occurred). All tumor
relapses (n = 7) occurred among the 44 persistently mrMRF-positive patients (P = 0.006)
(Table 2).
Fig 1. Representative images of a pre-CRTMRI (left column), post-CRT MRI (middle column), and
image of a recurred tumor obtained from a pCR patient who later developed tumor recurrence. (A)
50-year-old female with lung metastasis (relapse-free period, 22.9 months), (B) 70-year-old male with lung
metastasis (relapse-free period, 37.4 months). Positive MRI mesorectal fascia (short arrow), positive MRI
extramural vessel invasion (arrowhead), and a recurred tumor lesion (long arrow) are depicted.
doi:10.1371/journal.pone.0146235.g001
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On pre-CRT MRI, the mrEMVI status was statistically significant with respect to tumor
relapse (tumor relapse/negative vs. positive mrEMVI: n = 2/61 vs. 5/27; P = 0.026) (Table 2).
After CRT, six initially positive mrEMVI patients negatively converted. When we compared
the pre-/post-CRT MRI, persistently positive mrEMVI-status patients more frequently devel-
oped tumor relapse compared with negative (including negative conversion) mrEMVI-status
patients (tumor relapse/negative vs. positive mrEMVI: n = 2/67 vs. 5/21; P = 0.008) (Table 2).
When the mrMRF and mrEMVI status were considered together (Fig 2) based solely on
pre-CRT MRI results, the percentages developing a relapsed tumor were 22.7% (n = 5/22, both
factors positive) and 6.9% (n = 2/29, one factor positive), respectively, according to the num-
bers of positive risk factors. When pre-/post-CRTMRIs were analyzed together (Fig 3), the
percentages of tumor relapses increased to 27.8% (n = 5/18, both factors persistently positive)
and 7.7% (n = 2/26, one factor persistently positive), according to the number of persistently
positive parameters (Table 2).
Based on the pathology report of the surgical specimen, four patients (4.5%, n = 4/88) were
identified to carry pathologically confirmed metastatic regional LNs. These four patients were
each graded as having negative (n = 2) and positive (n = 2) mrN status on both pre- and post-
CRTMRIs. No tumor relapse occurred in these four patients (S2 Table). Pre-CRT mrN status
revealed no significant association with tumor relapse (tumor relapse/negative vs. positive
Table 2. Summary of the post-operative tumor relapse rate according to mrMRF status andmrEMVI status assessed on pre-CRTMRI alone (left)
and on pre- and post-CRT MRI together (right).
Pre-CRT MRI Pre-/post-CRT MRI
mrMRF (+) mrMRF (-) mrMRF (+) mrMRF (-)
mrEMVI (+) 22.7% relapse (n = 5/22) 0% relapse (n = 0/5) 27.8% relapse (n = 5/18) 0% relapse (n = 0/3)
mrEMVI (-) 6.9% relapse (n = 2/29) 0% relapse (n = 0/32) 7.7% relapse (n = 2/26) 0% relapse (n = 0/41)
(pre-CRT +: positive, -: negative; pre-/post-CRT +: persistently positive, -: persistently negative and negative conversion)
EMVI, extramural venous invasion; MRF, mesorectal fascia status; CRT, neoadjuvant concurrent chemoradiotherapy.
doi:10.1371/journal.pone.0146235.t002
Fig 2. Post-operative tumor relapse rate of pCR rectal cancer patients categorized according to pre-
CRTMRI features. The patients are grouped according to the level of the tumor distal margin (upper, middle,
or lower rectum) and pre-CRTMRI assessment of mrMRF status and mrEMVI status.
doi:10.1371/journal.pone.0146235.g002
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mrN: n = 3/50 vs. 4/38; P = 0.459). When the pre- and post-CRT MRIs were compared, 14
patients showed persistently positive mrN status (one patient developed a tumor relapse).
After CRT, 24 initially positive mrN positive patients experienced negative conversion and 50
patients were persistently negative. Consequently, 74 patients (six patients developed tumor
relapse) were mrN-negative (including negative conversion cases) without a significant differ-
ence in tumor relapse (P = 1.0), (S3 Table).
Kaplan-Meier analysis showed that patients with a positive mrMRF on pre-CRT MRI were
at an increased risk of post-operative tumor relapse compared with those with a negative
mrMRF (estimated five-year tumor relapse rate: 16.9% vs. 0%, respectively, P = 0.029; Fig 4A).
Similarly, patients with a positive mrEMVI on pre-CRT MRI were at an increased risk of
tumor relapse compared to those with a negative mrEMVI (estimated five-year tumor relapse
rate: 21.0% vs. 5.6%, respectively, P = 0.024; Fig 4B). No statistically significant difference was
observed in overall survival with respect to pre-CRT mrMRF (P = 0.165) and mrEMVI
(P = 0.234) status.
When we compared pre- and post-CRTMRIs, patients with persistently positive mrMRF
were at an increased risk of tumor relapse compared with those with a negative mrMRF,
including both persistently negative and negative conversion (estimated five-year tumor
relapse rate: 19.9% vs. 0%, respectively, P = 0.009; Fig 4C). Patients with a persistently positive
mrEMVI also showed an increased risk of tumor relapse compared with those with a negative
(including both persistently negative and negative conversion) mrEMVI (estimated five-year
tumor relapse rate: 27.5% vs. 4.9%, respectively, P = 0.003; Fig 4D). Upon comparison of pre-
and post-CRT MRIs, the overall survival did not show a statistically significant difference with
respect to mrMRF (P = 0.090) and mrEMVI (P = 0.106) status.
Discussion
In general, the prognosis for pCR rectal cancer patients is excellent [2, 7]. CRT and total mesor-
ectal excision for locally advanced rectal cancer has an effective role in decreasing the incidence
of local recurrence; however, its impact on systemic metastasis is not quite as impressive [1].
Fig 3. Post-operative tumor relapse rate of pCR rectal cancer patients categorized according to pre/
post-CRT MRI features. The patients are grouped according to the level of the tumor distal margin (upper,
middle, or lower rectum) along with the assessment results of mrMRF status and mrEMVI status derived from
both pre-CRT and post-CRTMRI (+: persistently positive, -: persistently negative and negative conversion).
doi:10.1371/journal.pone.0146235.g003
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Consequently, a post-operative tumor relapse in pCR-achieved patients usually occurs as a dis-
tant metastasis. In this study, we observed a 1.1% (n = 1/88) local recurrence rate and 6.8%
(n = 6/88) systemic recurrence rate, which together is equivalent to an overall 8.0% (n = 7/88)
tumor relapse rate. This is a risk comparable to the 2.6% local recurrence (n = 12/455) and
9.1% (n = 38/419) distant metastasis reported in a meta-analysis study on the long-term out-
come of pCR-achieved patients who also had undergone CRT and total mesorectal excision
[18]. We hypothesized that a risk stratification of pCR rectal cancer patients to selectively per-
form intensified treatment in high-risk subpopulations might be possible based on MRI fea-
tures. To the best of our knowledge, this is the largest study (n = 88) to analyze the MR
imaging parameters in association with the outcome of pCR rectal cancer patients who received
standard treatment.
The most important finding of this study was that the mrMRF status and mrEMVI status
were associated with a risk of post-operative tumor relapse. The mrMRF status corresponds to
the circumferential resection margin (CRM) status, which is a strong risk factor of local recur-
rence and an established prognostic factor [19–21]. Based on rectal cancer study populations
who have undergone CRT (but have not been filtered out for pCR cases), Taylor et al. demon-
strated that CRM involvement detected by either pre-operative MRI or pathological analysis of
the surgical specimen is significantly associated with distant metastasis [19]. Our results show
that positive mrMRF status serves as a risk factor for tumor relapse in pCR-achieved patients
as well.
Fig 4. Actuarial probability of the tumor relapse rate. Actuarial probability of the tumor relapse rate
according to pre-CRT assessment alone for (A) mrMRF status and (B) mrEMVI status. Actuarial probability
when both pre- and post-CRTMRIs are analyzed together for the tumor relapse rate according to (C) mrMRF
status and (D) mrEMVI status. (C-D) The positive group consists of patients with persistently positive findings
of mrMRF and/or mrEMVI on both pre- and post-CRTMRIs. The negative group includes both persistently
negative patients and negatively converted patients.
doi:10.1371/journal.pone.0146235.g004
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Positive mrEMVI status was another significant risk factor for post-operative tumor relapse.
Theoretically, tumor invaded vessels are a potential source of malignant embolic shower-pro-
moting systemic metastasis, and a positive mrEMVI is an independent risk factor for synchro-
nous metastasis [9]. Similarly, in previous studies (which have not been filtered for pCR
patients), EMVI detected either by an MRI or histopathology examination were both tumor
relapse risk factors in rectal cancer patients who had undergone CRT [22, 23].
CRT is effective for local tumor control but theoretically has only a limited systemic anti-
cancer effect [1]. Therefore, once a patient has been exposed to high-risk factors (such as a pos-
itive mrMRF or mrEMVI, in this study), which promote distant metastasis, it seems reasonable
to anticipate little preventive effect against systemic metastasis by CRT alone, whether or not
the primary cancer reaches pCR state. By definition, pCR patients only carry non-viable devas-
tated remnants of the tumor. As a result, we believe that pathological examination of pCR-
achieved patients will probably underestimate the pre-treatment tumor risk factors, even if
positive findings were initially present. In contrast, MRI can assess the tumor both before and
after CRT. Therefore, at least for the post-operative tumor relapse risk stratification of pCR-
achieved patients, we suggest that MRI parameters could be more important than histologic
parameters. Moreover, MRI has a practical advantage in that it can be applied to non-surgically
treated patients, whose histologic assessment is impossible.
Our data suggest that a single pre-CRTMRI is sufficient to assess mrMRF and mrEMVI sta-
tus for the prediction of the high-risk group post-operative tumor relapse. However, when the
pre- and post-CRT MRIs were analyzed together to identify the patients with persistently posi-
tive risk factors, a slightly more efficient risk stratification was possible (Table 2).
Other generally recognized adverse features of rectal cancer treatment include high T and/
or N stages, a low rectal location of the lesion, and a high tumor regression grade [5, 24–26].
We analyzed factors such as the pre-treatment CEA level, tumor level, tumor volume, volume
reduction rate, mrTRG, mrT, and mrN status. However, under the current context of pCR rec-
tal cancer patients, statistically significant relevance was not observed with respect to the rate
of post-operative tumor relapse (S2 and S3 Tables).
In our study population, 4.5% (n = 4/88) of patients were identified to carry pathologically
confirmed metastatic LNs, which is a rate similar to one (5%, n = 26/509) that was reported in
a large-scale meta-analysis [18]. The ypN stage has been reported to be a predictor for overall
tumor relapse [21]; however, none of the four patients in our study developed post-operative
tumor relapse. In combination with previous studies [18], this observation supports the notion
that less invasive strategies (such as local excision or the ‘wait and see’ approach), which omit
histological nodal assessment, should be adopted with caution.
This study has several limitations. Firstly, the events of tumor relapse (n = 7) were insuffi-
cient to establish a solid conclusion, and multivariable analysis was not possible. Nevertheless,
this is the largest single-center study that has analyzed the MRI features of pCR rectal cancer
patients who have undergone standard radical surgery. Secondly, this study is retrospective in
nature, and adjuvant chemotherapy was not standardized. Unexpectedly, all the tumor-
recurred patients (n = 7) were treated with adjuvant chemotherapy before their tumors
relapsed; therefore, the role of adjuvant chemotherapy remains ambiguous. We acknowledge
that a randomized prospective study is necessary to validate our findings.
In conclusion, our data suggest that a positive mrMRF and/or positive mrEMVI status are
associated with increased risk of tumor relapse in pCR-achieved rectal cancer patients. This
can be applied for post-operative risk stratification to individualize therapeutic strategies.
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Supporting Information
S1 Fig. MR-based criteria used to classify the rectal cancer level. The Sagittal T2WI of pre-
CRTMRI images was used to draw three lines on PACS which each connected the center of
symphysis pubis with the 1) sacral promontory (white line), 2) the peritoneal reflection (arrow-
head, dotted black line) and 3) the intervertebral junction between the fifth sacral bone and
coccyx (black line) to divide the rectum into three compartments (upper rectum: UR, middle
rectum: MR and lower rectum: LR). The location of the distal tumor margin assigned the spe-
cific rectal compartment of the patient. This example image shows a rectal cancer (arrows)
located at the anterior aspect of the rectum, which extends into the middle rectal compart-
ment.
(PDF)
S1 Table. Summary of pre-operative MRI findings of the seven pCR-achieved patients who
developed post-operative tumor relapse.
(DOCX)
S2 Table. Summary of the univariate analyses of clinical variables associated with tumor
relapse in pCR.
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S3 Table. Summary of the pre-operative MRI findings of pCR patients according to tumor
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